Showing results (391-400 of 403) with videos related to

Sort By:
Pageof 41
Blood Advances|September 13, 2021
Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapyDavid A Bond, Jeffrey M Switchenko, Diego Villa, et al.
The Journal of Pediatrics|September 14, 2024
Impact of Elevated Serum Triglycerides on Children with Acute Recurrent or Chronic Pancreatitis from INSPPIRE-2Zachary M Sellers, Matthew J Giefer, Fuchenchu Wang, et al.
Blood Advances|December 14, 2022
Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphomaNarendranath Epperla, Jeffrey Switchenko, Veronika Bachanova, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|June 16, 2026
Pancreatitis Risk Genes Play a Major Role in Pediatric Pancreatitis: Insights From INSPPIREMaisam Abu-El-Haija, Wenying Zhang, Fuchenchu Wang, et al.
Vaccine|December 8, 2022
Added value of the measles-rubella supplementary immunization activity in reaching unvaccinated and under-vaccinated children, a cross-sectional study in five Indian districts, 2018-20C Prosperi, J W V Thangaraj, A Z Hasan, et al.
Blood Advances|May 28, 2025
Infection after CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: real-world analysis from CIBMTRKitsada Wudhikarn, Megan M Herr, Min Chen, et al.
Journal of Hematology & Oncology|July 16, 2022
Predictive factors and outcomes for ibrutinib in relapsed/refractory marginal zone lymphoma: a multicenter cohort studyNarendranath Epperla, Qiuhong Zhao, Sayan Mullick Chowdhury, et al.
Blood Neoplasia|March 23, 2026
Impact of age on outcomes after CD19 CAR T-cell therapy for large B-cell lymphomasAbu-Sayeef Mirza, Chitra Hosing, Francine Foss, et al.
Blood|July 15, 2025
Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamabTaylor R Brooks, Emily C Zabor, Yohanna Bedelu, et al.
Blood Advances|December 11, 2025
Benefit of Rituximab Maintenance After First-line Bendamustine-Rituximab in Patients with Mantle Cell LymphomaYucai Wang, Melissa C Larson, Steven R Hwang, et al.
Pageof 41